OKYO OKYO Pharma

OKYO Pharma Announces Participation in May 2024 Investor Conferences

OKYO Pharma Announces Participation in May 2024 Investor Conferences

LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.

Conference: Aegis Capital Virtual Healthcare Conference

Date: Wednesday May 8, 2024, 11 AM EST

Location: Virtual

Presenter: Gary Jacob, PhD, Chief Executive Officer

Conference: Citizens JMP Securities Life Sciences Conference

Date: Monday May 13, 2024, 10:30 AM EST

Location: New York, NY

Presenter: Gary Jacob, PhD, Chief Executive Officer

About OKYO

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit .

Enquiries:

OKYO Pharma LimitedGary S. Jacob, Chief Executive Officer917-497-7560
Business Development & Investor RelationsPaul Spencer+44 (0)20 7495 2379







EN
08/05/2024

Underlying

OKYOOKYO Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OKYO Pharma

 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordina...

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the “Offering”) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ord...

February 13, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Public Offering of Ordinary Shares

OKYO Pharma Announces Public Offering of Ordinary Shares LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the “Offering”). All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Transition of At-The-Market Equity Offering Faci...

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, a leading healthcare-focused investment bank as the sales agent, replacing its previous ATM facility with B. Riley Securities Inc. ...

February 11, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Strengthens World Class Leadership Team with Appointment o...

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development program in neuropathic corneal pain (NCP), leveraging urcosimod’s FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class opht...

February 10, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results fo...

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that an abstract on its lead candidate, urcosimod (formerly OK-101), has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. ...

January 30, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch